S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Price, News & Analysis

$6.20
+0.38 (+6.52%)
(As of 03/18/2024 ET)
Today's Range
$5.80
$6.26
50-Day Range
$5.39
$7.29
52-Week Range
$1.61
$7.45
Volume
1.26 million shs
Average Volume
1.75 million shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.76

Autolus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
28.3% Upside
$7.96 Price Target
Short Interest
Healthy
1.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Autolus Therapeutics in the last 14 days
Based on 25 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

Medical Sector

317th out of 947 stocks

Biological Products, Except Diagnostic Industry

44th out of 159 stocks

AUTL stock logo

About Autolus Therapeutics Stock (NASDAQ:AUTL)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

AUTL Stock Price History

AUTL Stock News Headlines

Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
The only AI company you should be looking at
This is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.
Q4 2023 Autolus Therapeutics PLC Earnings Call
They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
Autolus Therapeutics's Earnings Outlook
AUTL Jun 2024 10.000 call
AUTL Mar 2024 2.500 call
Autolus Therapeutics Ltd (AUTL)
Vaxcyte, Inc.
See More Headlines
Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/18/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
399
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.96
High Stock Price Target
$10.00
Low Stock Price Target
$4.80
Potential Upside/Downside
+25.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-148,840,000.00
Pretax Margin
-3,180.50%

Debt

Sales & Book Value

Annual Sales
$1.70 million
Book Value
$1.73 per share

Miscellaneous

Free Float
172,577,000
Market Cap
$1.44 billion
Optionable
Optionable
Beta
1.90
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Christian Martin Itin Ph.D. (Age 60)
    CEO & Director
    Comp: $2.73M
  • Dr. Martin Pule M.D. (Age 52)
    MBBS, Founder, Senior VP & Chief Scientific Officer
  • Mr. Christopher Vann (Age 59)
    Senior VP & COO
  • Mr. David Brochu (Age 68)
    Senior VP & Chief Technical Officer
  • Mr. Brent Rice (Age 58)
    Senior VP, Chief Commercial Officer & Site Head of US
  • Dr. Edgar E. W. Braendle M.D. (Age 64)
    Ph.D., Senior VP & Chief Development Officer
  • Mr. Robert F. Dolski (Age 54)
    Chief Financial Officer
  • Ms. Olivia Manser
    Director of Investor Relations
  • Dr. Chris Williams (Age 44)
    Senior Vice President of Corporate Development
  • Mr. Alexander Swan
    Chief Human Resources Officer

AUTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUTL shares.
View AUTL analyst ratings
or view top-rated stocks.

What is Autolus Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 1 year price targets for Autolus Therapeutics' shares. Their AUTL share price targets range from $4.80 to $10.00. On average, they anticipate the company's share price to reach $7.96 in the next year. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for AUTL
or view top-rated stocks among Wall Street analysts.

How have AUTL shares performed in 2024?

Autolus Therapeutics' stock was trading at $6.44 at the beginning of the year. Since then, AUTL shares have decreased by 3.6% and is now trading at $6.2050.
View the best growth stocks for 2024 here
.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a drop in short interest in the month of February. As of February 29th, there was short interest totaling 2,770,000 shares, a drop of 10.6% from the February 14th total of 3,100,000 shares. Based on an average daily trading volume, of 1,650,000 shares, the short-interest ratio is presently 1.7 days.
View Autolus Therapeutics' Short Interest
.

When is Autolus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUTL earnings forecast
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) released its earnings results on Tuesday, November, 2nd. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.04. The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.25 million. During the same quarter last year, the company earned ($0.72) EPS.

What ETF holds Autolus Therapeutics' stock?

Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio.

What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include TFG Asset Management GP Ltd (4.60%), Armistice Capital LLC (2.21%), Price T Rowe Associates Inc. MD (1.73%), Price T Rowe Associates Inc. MD (1.73%), Perpetual Ltd (1.19%) and Perceptive Advisors LLC (1.05%).

How do I buy shares of Autolus Therapeutics?

Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUTL) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners